Anemia in Chronic Kidney Disease : Role of Hypoxia Inducible Factor Stabilizer
DOI:
https://doi.org/10.32539/bsm.v5i5.234Keywords:
Chronic Kidney Disease, Anemia, Erythropoiesis-stimulating Agents, Hypoxia Inducible Factor Stabilizer.Abstract
Anemia contributes to increased morbidity and mortality in chronic kidney disease patients. The pathogenesis of anemia in these patients is multifactorial, but the contribution of erythropoietin deficiency becomes greater as glomerular filtration rate declines which related to decreased nephron mass. The current standard of care includes supplemental iron, erythropoiesis-stimulating agents (ESA), and red blood cell transfusions, although each has drawbacks. Lately, concern has arisen following randomized clinical trials showing that higher hemoglobin targets and/or high ESA doses may cause significant harm including increasing cardiovascular and thrombotic events, and even death. Recent experimental and clinical studies show the promising efficacy of hypoxia inducible factor (HIF) stabilizer which stimulates endogenous erythropoietin production and enhance iron availability.
Authors
- Emilia1*
- Zulkhair Ali2
- 1Trainee of Nephrology and Hypertension, Internal Medicine Department, Faculty of Medicine, Universitas Sriwijaya, Palembang, South Sumatera, Indonesia.
- 2Division of Nephrology and Hypertension, Internal Medicine Department, Faculty of Medicine, Universitas Sriwijaya, Palembang, South Sumatera, Indonesia.
Corresponding author Emilia — emilia160781@gmail.com
Article history
- Submitted
- Accepted
- Published
Downloads
Published
Issue
Section
License
Copyright and licensing
Copyright in each article remains with the author(s). Authors grant Bioscientia Medicina: Journal of Biomedicine and Translational Research a non-exclusive right of first publication and the right to identify itself as the original publisher. No exclusive transfer of copyright is required.
All articles are published under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License (CC BY-NC-SA 4.0): https://creativecommons.org/licenses/by-nc-sa/4.0/. Users may copy, redistribute, remix, transform, and build upon the material for non-commercial purposes, provided appropriate attribution is given, a link to the license is supplied, changes are indicated, and adaptations are distributed under the same license.
The license applies to the article's scholarly content unless a credit line states otherwise. Third-party material may be subject to separate rights. Authors retain patent, trademark, moral, and research-data rights. The copyright year follows the article's publication date.
